Aytu BioPharma, Inc.
AYTUHealthcare|Drug Manufacturers - Specialty & Generic|US
$1.83
+0.02 (+1.10%)
Cash / Share
$2.14
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07169162 ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder | Attention Deficit Hyperactivity Disorder | P4 | Withdrawn | — | RCT, Double-blind | ADZENYS XR-ODT, Placebo Oral Tablet |
| NCT05463679 Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. | Vascular Ehlers-Danlos Syndrome | P3 | SUSPENDED | 260 | RCT, Double-blind | Enzastaurin, Placebo |
| NCT04758260 Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men Whose Partners Will Undergo Through an Egg Donation Cycle | Compare the sORP Rate in Sperm Samples, Obtained by the Mioxsys System, Before and After 2.5 Months Antioxidant Men Supplements Treatment (Fertybiotic Man) | N/A | Withdrawn | — | Open-label | — |
| NCT04572399 UVA Light Device to Treat COVID-19 | Coronavirus | N/A | Completed | 5 | Open-label | — |
| NCT02839447 A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0 | Male Infertility | Withdrawn | — | — | — | |
| NCT02786459 Detection and Localization of Carcinoma Using High Resolution Transrectal Imaging - Proof of Concept Study | Prostate Cancer | N/A | Completed | 18 | Open-label | — |
| NCT05166915 Respiratory COVID-19: A Randomized, Sham-Controlled Study | COVID-19 Pneumonia, Acute Respiratory Distress Syndrome | N/A | Withdrawn | — | RCT, Double-blind | — |